In early October 2024, the Republic of Rwanda began vaccinating frontline health workers in a Phase 2 rapid response open-label clinical trial to combat the reaction to the ongoing Marburg virus disease (MVD) outbreak, which has already claimed 14 lives.

As the 2024-2025 Respiratory Syncytial Virus (RSV) season expands in the United States, one approved vaccine shared some positive news.  GSK plc today announced new data from a phase 3 clinical trial evaluating the efficacy and safety of a single dose of AREXVY RSV vaccine against lower respiratory tract disease (LRTD) over three full RSV seasons.

Bats spread rabies in Chicago, Ontario, Minneapolis in 2024

Vicebio Ltd. today announced a $100 million Series B financing led by TCGX and others. Vicebio is developing next-generation vaccines for respiratory viruses utilizing its proprietary Molecular Clamp technology, which was discovered at the University of Queensland (UQ). The Molecular Clamp technology applies to a wide range of viruses, including Respiratory Syncytial Virus (RSV), Human Metapneumovirus (hMPV), Parainfluenza virus, Influenza, and Coronaviruses, as confirmed by promising preclinical and clinical studies.

As the global measles outbreak continues in 2024, a 32nd U.S. state confirmed its initial case. The Tennessee Department of Health (TDH) recently confirmed that a Tennessee resident who recently traveled internationally is recovering from a measles infection. As of September 14, 2024, TDH has not identified additional measles cases in Tennessee. The last year in which TDH reported positive measles cases in Tennessee was 2019.

While there is an approved Ebola virus disease (EVD) vaccine, the U.S. government continues to invest in human monoclonal antibody (mAb) therapy during Zaire ebolavirus outbreaks in Africa. The initial Zaire Ebolavirus disease (EVD) case was confirmed in 1976, Since then, more than 30 EVD outbreaks have been reported.